WO2011153247A1 - Polythérapies - Google Patents

Polythérapies Download PDF

Info

Publication number
WO2011153247A1
WO2011153247A1 PCT/US2011/038769 US2011038769W WO2011153247A1 WO 2011153247 A1 WO2011153247 A1 WO 2011153247A1 US 2011038769 W US2011038769 W US 2011038769W WO 2011153247 A1 WO2011153247 A1 WO 2011153247A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
formula
pharmaceutically acceptable
compound
Prior art date
Application number
PCT/US2011/038769
Other languages
English (en)
Inventor
J. Michael Davenport
Paul Covington
Gail Mcintyre
Original Assignee
Furiex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furiex Pharmaceuticals, Inc. filed Critical Furiex Pharmaceuticals, Inc.
Publication of WO2011153247A1 publication Critical patent/WO2011153247A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the invention relates to a combination product or medicament or therapy comprising at least one substituted pyrrole derivative and one or more dyslipidemic agent(s).
  • pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agent(s), together with at least one pharmaceutically acceptable carrier.
  • methods for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of combination pharmaceutical composition comprising at least one substituted pyrrole derivative and one or more dyslipidemic agent(s).
  • Atherosclerosis is characterized by the deposition of fatty substances, primarily cholesterol, resulting in plaque formation on the inner surface of the arterial wall and degenerative changes to the arteries.
  • cardiovascular disorders including myocardial infarction, coronary heart disease, hypertension and hypotension, cerebrovascular disorders including stroke, cerebral thrombosis and memory loss due to stroke; peripheral vascular disease and intestinal infarction are caused by blockage of arteries and arterioles by atherosclerotic plaque.
  • Atherosclerotic plaque formation is multi-factorial in its production.
  • Numerous studies have demonstrated that a low plasma concentration of high-density lipoprotein (HDL) cholesterol is a powerful risk factor for the development of atherosclerosis.
  • HDL is one of the major classes of lipoproteins that function in the transport of lipids through the blood.
  • the major lipids found associated with HDL include cholesterol; cholesteryl ester, triglycerides, phospholipids and fatty acids.
  • the other classes of lipoproteins found in the blood are low density lipoprotein (LDL), intermediate density lipoprotein (IDL), and very low density lipoprotein (VLDL). Since low levels of HDL cholesterol increase the risk of atherosclerosis, methods for elevating plasma HDL cholesterol are be beneficial for the treatment of atherosclerosis and other diseases associated with the accumulation of lipid in the blood vessels.
  • compositions comprising CETP inhibitor and other therapeutic agents, for example, HMG-CoA reductase inhibitor, a PPAR agonist or fibrate, for the treatment of diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL- cholesterol and triglycerides.
  • 6,534,088 discloses combinations of HMG-CoA reductase inhibitor and fibrate for treatment of patients with dyslipidemia, hyperlipidemia, hypercholesterolemia and related conditions. Combinations of fibrate and HMG-CoA reductase inhibitor have also been disclosed in U.S. Patent No. 6,51 1,985; PCT Publication Nos. WO 2005/034908, WO 03/013607, WO 01/37831.
  • U.S. Patent No. 6,420,417 discloses combinations of ileal bile acid transport inhibiting benzothiepines and HMG-CoA reductase inhibitors for treating hyperlipidemic conditions.
  • WO 04/004777 discloses CETP inhibitors and antihypertensive agents as well as optionally HMG-CoA reductase inhibitors.
  • Inflammatory diseases are all characterized by the presence of mediators that recruit and activate different inflammatory cells which release enzymes or oxygen radicals causing symptoms, the persistence of inflammation and when chronic, destruction or disruption of normal tissue.
  • PCT Publication No. WO 04/019985 discloses pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteriods.
  • PCT Publication No. WO 02/096422 discloses combinations of a dopamine D2 -receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases.
  • PCT Publication No. WO 03/066063 discloses pharmaceutical compositions comprising 17alpha-furanylesters of 17beta- carbothiate androstanes with a muscarinic receptor antagonists.
  • 2004/0097555 discloses pharmaceutical agents comprising one or more kinds of a p38 MAP kinase inhibitor and/or a TNF- alpha production inhibitor and one or more kinds of drugs selected from (1) a non-steroidal anti-inflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an-anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination, which has been said to be useful as a prophylactic or therapeutic agent of the diseases rheumatism, arthritis and other diseases.
  • drugs selected from (1) a non-steroidal anti-inflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an-anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination, which has been said to be useful as a prophylactic or therapeutic agent of the diseases rheum
  • WO 95/28926 discloses a pharmaceutical composition for treating multiple sclerosis comprising an effective amount of a combination of a PDE IV inhibitor and an anti-inflammatory or immunomodulatory drug in a pharmaceutically acceptable carrier.
  • PCT Publication No. WO 01/13953 and U.S. Publication No. 20040034087 disclose the combined administration of PDE inhibitors and beta 2 adrenoceptor agonists for the treatment of respiratory tract disorders.
  • PCT Publication No. WO 01/32127 discloses the treatment of pulmonary diseases such as chronic obstructive pulmonary disease or asthma by administering a phosphodiesterase 4 inhibitor in combination with anti-inflammatory corticosteroid.
  • WO 2004/067006 discloses treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist.
  • PCT Publication No. WO 2005/041864 discloses a method for the prevention and/or treatment of respiratory inflammation, and in particular asthma and COPD, in a subject in need of such prevention or treatment, the method comprising administering to the subject a cycloogenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor.
  • compositions and combination therapies of this invention are met by the pharmaceutical compositions and combination therapies of this invention. Additionally, the pharmaceutical compositions and therapeutic methods of this invention achieve other advantages discussed more fully below.
  • combination products or medicaments comprising at least one novel substituted pyrrole derivative, and a dyslipidemic agent, for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases.
  • compositions comprising a)
  • therapeutically effective amounts of a substituted pyrrole derivative optionally together with at least one pharmaceutically acceptable carrier, and b) therapeutically effective amounts of one or more dyslipidemic agent(s), optionally together with at least one pharmaceutically acceptable carrier.
  • Also provided herein is a single pharmaceutical composition comprising at least one substituted pyrrole derivative, and one or more dyslipidemic agents, with at least one pharmaceutically acceptable carrier.
  • compositions comprising therapeutically effective amounts of at least one substituted pyrrole derivative, and one or more dyslipidemic agents, optionally together with at least one
  • compositions comprising a first
  • compositions comprising therapeutically effective amounts of at least one substituted pyrrole derivative, optionally together with at least one pharmaceutically acceptable carrier; and a second pharmaceutical composition comprising one or more dyslipidemic agents, optionally together with at least one pharmaceutically acceptable carrier.
  • the separate compositions can be given separately, simultaneously or sequentially.
  • kits containing a single composition comprising therapeutically effective amounts of at least one substituted pyrrole derivative, and one or more dyslipidemic agents, optionally together with at least one
  • kits containing a first pharmaceutical composition of at least one substituted pyrrole derivative, optionally together with at least one pharmaceutically acceptable carrier; a second pharmaceutical composition of one or more dyslipidemic agents, optionally together with at least one pharmaceutically acceptable carrier; prescribing information and a container.
  • the prescribing information may describe the administration and or use of these separate compositions simultaneously, separately or sequentially.
  • cardiovascular diseases Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of any of the above-described combination pharmaceutical compositions, including, for example, the pharmaceutical compositions comprising at least one substituted pyrrole derivative and a dyslipidemic agent.
  • One specific embodiment is a method of preventing or treating a disorder related to lipid levels in a subject selected from the group consisting of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a subject in need thereof about 40 mg/dose to about 160 mg/dose of a compound selected from the group consisting of the compound of Formula I:
  • gemfibrozil or pharmaceutically acceptable salts thereof, and about 300 mg/dose to about 600 mg/dose of gemfibrozil, wherein the gemfibrozil is administered simultaneously, separately or sequentially with the compounds of Formula I and Formula II.
  • the combination product or medicament, pharmaceutical composition, pharmaceutical package, pharmaceutical kit and method for treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases involve therapeutically effective amounts of at least one substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, antiinflammatory agents or mixtures thereof.
  • Substituted pyrrole derivatives may be compounds having the structure of Formula
  • Ri is Q-C6 alkyl, C3-C6 cycloalkyl, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C ⁇ -Ce alkyl, cyano, or C1-C3 perfluoroalkyl);
  • R 2 is optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C]-C 6 alkyl, C 3 -C 6 cycloalkyl, acetyl, or sulfonamide);
  • R3 is optionally substituted Ci-C 6 alkyl or C 3 -C 6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, Q-C3 alkoxy and protected hydroxyl); or
  • R3 is -NR 8 R9, wherein R g and R are optionally substituted C ⁇ -C 6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C1-C3 alkoxy and protected hydroxyl);
  • R5 and R6 are independently hydrogen, or aryl substituted with Ci-C 6 alkyl substituted with up to two substituents independently selected from hydroxyl, protected hydroxyl, and halogens,
  • R 2 is phenyl only when R 5 or 3 ⁇ 4 is phenyl substituted with hydroxyalkyl.
  • Particular illustrative compounds of Formula I include: (3R,5R)-7-[2-(4- fiuorophenyl)-5- isopropyl-3-phenyl-4-[(4- hydroxymethylphenylamino)carbonyl]-pyrrol- l-yl]-3, 5-dihydroxy-heptanoic acid.
  • Substituted pyrrole derivatives may also be compounds having the structure of Formula II:
  • Ri is Ci-C 6 alkyl, C3-C6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, Q-C6 alkyl, cyano and Q-C3
  • R 2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino);
  • R 3 is optionally substituted Ci-C 6 alkyl or C3-C6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, Cj-C 3 alkoxy, and protected hydroxyl); R 3 can also be - R6R7 wherein R ⁇ and R 7 are optionally substituted Q- C6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, Q-C 3 alkoxy, and protected hydroxyl);
  • R4 is -COR 10 (wherein Ri 0 is selected from Ci-C 2 alkoxy, hydroxyl and -NRnRi 2 (wherein Rn and Ri are independently selected from hydrogen, alkyl, aryl, C 3 -C 7 cycloalkyl, aralkyl and Rn and R] 2 together form 5-7 membered ring with one or more optional heteroatom(s) wherein
  • heteroatom(s) is/are independently selected from nitrogen, oxygen and sulphur
  • R 5 is hydrogen, Ci-Ce alkyl or C 3 -C 6 cycloalkyl, optionally substituted aryl or aralkyl (wherein the substituents are selected from halogens, cyano, optionally substituted Ci-C 6 alkyl (wherein the substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s))), optionally substituted amino, acetyl, trifluoromethyl and C]-C 6 alkoxycarbonyl.
  • Particular illustrative compounds of Formula II include: (3R,5R)-7-[2-(4- fluorophenyl)-5-isopropyl-3-phenyl-4-[4-carboxyphenyl)amino) carbonyl]-pyrrol-l-yl]- 3,5-dihydroxy-heptanoic acid).
  • NRK-49F Fibroblast
  • L6 Myoblast
  • Dyslipidemic agents useful in the compositions and methods of the invention can be selected from, but are not limited to: cholesteryl ester transfer protein (CETP) inhibitors, fibric acid derivatives/fibrates, antihypertensive agents, bile acid sequestrants, Acyl CoA -cholesterol acyltranferase inhibitors, cholesterol absorption inhibitors or other dyslipidemic agents.
  • CETP cholesteryl ester transfer protein
  • Preferred dyslipidemic agents useful in the compositions and methods of the invention are fibric acid derivatives or fibrates selected, for example, from compounds described in U.S. Patent Nos. 4,051,143; 3,723,446; 4,058,552; 3,674,836; 3,781,328; 3,948,943; 3,716,583 and 3,984,413.
  • Preferred examples of fibric acid derivatives or fibrates include, but are not limited to, etofibrate, fenofibrate, clofibrate, gemfibrozil, bezafibrate, ciprofibrate, clinofibrate or theofibrate.
  • Preferred embodiments of the invention include pharmaceutical compositions containing about 80mg of a compound of Formula I and about 600mg of gemfibrozil.
  • compositions containing about 80mg of a compound of Formula II and about 600mg of gemfibrozil include pharmaceutical compositions containing about 80mg of a compound of Formula II and about 600mg of gemfibrozil.
  • gemfibrozil an inhibitor of OATPIB l
  • AUC area under the curve
  • Cmax maximum concentration of compounds of Formula II, when administered concurrently with gemfibrozil.
  • cardiac disease refers to any disorder in any of the various parts of cardiovascular system, which is made up of heart and blood vessels throughout the body.
  • the combination pharmaceutical compositions disclosed herein are intended to be used for the treatment or prophylaxis of disease or disorder of heart (cardio) and the disease or disorder of blood vessels (vascular).
  • Some examples of cardiovascular disease include, but are not limited to, arteriosclerosis, atherosclerosis,
  • hypercholesterolemia hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypertension, stroke, ischemia, peripheral vascular disease, peripheral arterial disease, coronary heart disease, myocardial infarction, cerebral infraction, myocardial
  • microvascular disease osteoporosis, osteopenia, angina, resterosis or diabetes and related disorders.
  • inflammatory disease refers to any disease, condition, trait, genotype or phenotype characterized by an inflammatory or allergic process as is known in the art such as inflammation, acute inflammation, chronic inflammation, respiratory disease, atherosclerosis, restenosis, asthma, COPD, allergic rhinitis, atopic dermatitis, septic shock, rheumatoid arthritis, inflammatory bowel disease, inflammatory pelvic disease, pain, ocular inflammatory disease, celiac disease, Leigh Syndrome, Glycerol Kinase Deficiency, Familial eosinophilia (FE), autosomal recessive spastic ataxia, laryngeal inflammatory disease; Tuberculosis, Chronic cholecystitis,
  • Bronchiectasis Silicosis and other pneumoconioses, and any other inflammatory disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.
  • pharmaceutical package refers to any package useful for stable storage of the dosage form, comprising (a) single pharmaceutical composition comprising a therapeutically effective amount of at least one substituted pyrrole derivative, at least one dyslipidemic agent, antiobesity, or antihyperglycaemic agent, antiinflammatory agent or mixtures thereof, optionally together with pharmaceutically acceptable carriers, or (b) a first pharmaceutical composition comprising a therapeutically effective amount of at least one substituted pyrrole derivative, optionally together with a pharmaceutically acceptable carrier, a second pharmaceutical composition comprising at least one dyslipidemic agent, antiobesity, or antihyperglycaemic agent, anti-inflammatory agent or mixtures thereof, optionally together with pharmaceutically acceptable carriers.
  • the package may, for example, be a glass, plastic, strip pack or blister pack.
  • pharmaceutical kit refers to a kit containing (a) a single pharmaceutical composition comprising a therapeutically effective amount of at least one substituted pyrrole derivative; one or more dyslipidemic agents, antiobesity,
  • antihyperglycaemic agents anti-inflammatory agents or mixtures thereof, optionally together with pharmaceutically acceptable carriers; prescribing information and a container, or (b) a first pharmaceutical composition comprising a therapeutically effective amount of at least one substituted pyrrole derivative, optionally together with
  • a second pharmaceutical composition comprising one or more dyslipidemic agents, antiobesity, antihyperglycaemic agents, anti- inflammatory agents or mixtures thereof, optionally together with pharmaceutically acceptable carriers; prescribing information and a container.
  • the prescribing information may include pharmacodynamics, pharmacokinetics, indications and usages, direction of administration, warnings, dosage or adverse effects of each pharmaceutical.
  • the container in the kit provides means for separating the first and second pharmaceutical compositions.
  • the container may, for example, be a divided bottle or divided foil packet, for example, blister pack.
  • composition refers to, in one embodiment; a single pharmaceutical composition comprising at least one substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity, antihyperglycaemic agents, anti-inflammatory agents or mixtures thereof, optionally together with
  • the combination pharmaceutical composition in a second embodiment, refers to a first pharmaceutical composition comprising
  • a second pharmaceutical composition comprising one or more dyslipidemic agents, antiobesity, antihyperglycaemic agents, antiinflammatory agents or mixture thereof, optionally together with pharmaceutically acceptable carriers.
  • the separate pharmaceutical composition can be administered simultaneously, separately or sequentially.
  • the pharmaceutically acceptable salts include, for example, alkali metal (e.g., sodium or potassium) or alkaline earth metal (e.g., calcium or magnesium) salts and addition salts of acids or bases.
  • Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
  • Example of such inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric acid and like.
  • organic acids include, but not limited to, aliphatic, cycloaliphatic, aromatic, heterocyclic, carboxylic and sulfonic classes of organic acids, such as, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, dihydroxytartaric acid, citric, ascorbic, glucuronic, maleic, tumeric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p- hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, algenic, beta-hydroxybutyric, cyclohexylaminosulfonic, galact
  • Pharmaceutically acceptable base addition salts include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, and procaine and the like.
  • the present invention also includes prodrugs of the active agents disclosed herein.
  • prodrugs will be functional derivatives of these compounds, which are readily convertible in vivo into the required compound.
  • Conventional procedure for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", Bundgaard, Elsevier, 1985.
  • the present invention also includes metabolites, which become active upon introduction into the biological system. Where the compounds have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds according to invention possess two or more chiral centers, they may additionally exist as diastereomers. All such individual isomers and racemates therefore are encompassed within the scope of the present invention.
  • some of the crystalline forms for compounds described herein may exist as polymorphs and are included in the present invention.
  • some of the compounds described herein may form solvates with water (i.e., hydrates) or common organic solvents. Such solvates are also encompassed within the scope of this invention.
  • a single composition containing at least one substituted pyrrole derivative and one or more dyslipidemic agents may be suitable for oral, parenteral, topical, or transdermal administration.
  • the compositions may be formulated to provide immediate or sustained release of the therapeutic agents.
  • the agents described herein can be administered concurrently as individual formulations, but will generally be administered as an admixture with a suitable "pharmaceutically acceptable carrier".
  • pharmaceutically acceptable carrier is intended to include non-toxic, inert solid, semisolid or liquid diluents(s), encapsulating material or formulation auxiliary of any type.
  • Solid form preparations for oral administration may include capsules, tablets, pills, powder, granules and suppositories.
  • the active compound(s) are mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate, dicalcium phosphate and/or a filter an extender such as starch, lactose, sucrose, glucose, mannitol and silicic acid; binders such as carboxymethyl cellulose, alginates, gelatins, polyvinylpyrrolidinone, sucrose, acacia; disintegrating agents such as agar-agar, calcium carbonate, potato starch, aliginic acid, certain silicates and sodium carbonate; absorption accelerators such as quaternary ammonium compounds; wetting agents such as cetyl alcohol, glycerol, monostearate; adsorbents such as kaolin; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethyleneglycol,
  • the dosage form may also comprise buffering agents.
  • the solid preparation of tablets, capsules, pills, granules can be prepared with coating and shells such as enteric coating and other coatings well known in the pharmaceutical formulating art.
  • Liquid form preparation for oral administration includes pharmaceutically acceptable emulsions, solution, suspensions, syrups and elixirs.
  • active compound is mixed with water or other solvent, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (such as cottonseed, groundnut, corn, germ, olive, castor and sesame oil), glycerol and fatty acid ester of sorbitan and mixtures thereof.
  • solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (such
  • the oral composition can also include adjuvants such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents and perfuming agent.
  • adjuvants such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents and perfuming agent.
  • Injectable preparations such as sterile injections, aqueous or oleaginous suspensions may be formulated according to the art using suitable dispersing or wetting and suspending agents.
  • suitable dispersing or wetting and suspending agents include water, Ringer's solution and isotonic sodium chloride.
  • Dosage form for topical or transdermal administration includes ointments, pastes, creams, lotions, gel, powders, solutions, spray, inhalants or patches.
  • the active compound(s) are admixed under sterile condition with a pharmaceutically acceptable carrier and any needed preservatives or buffer as may be required.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active components.
  • the formulations described herein may be formulated so as to provide quick sustained, or delayed release of the active ingredient after administration to the patient by employing procedure well known to the art.
  • the composition may be administered as a depot formulation that permits sustained release, limits access to general circulation.
  • Such a formulation may be provided as a slow release implant, be microencapsulated, or attached to a biodegradable polymer.
  • the compound is administered in a sustained release formulation as a tablet or capsule.
  • a sustained release formulation is a preparation that releases the active component over a desired period of time after administration.
  • a sustained release formulation is prepared by applying a biodegradable, bioerodible or bioabsorbable polymeric formulation that is compatible on the surface of the active component. Examples of sustained release formulation include, but are not limited to, hydroxypropylmethylcellulose (HPMC), hydrogenated vegetable oil (HVO),
  • ethylcellulose polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacryl - amidephenol, polyhydroxy - ethylaspartamidephenol, or polyethyleneoxidepolylysin substituted with palmitoyl residues, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-pyrans, or polycyano acrylates.
  • biodegradable means that the polymeric formulation degrades overtime by the action of enzymes, by hydrolytic action and/or by other similar mechanisms in the human body.
  • bioerodible it is meant that the polymeric formulation erodes or degrades over time due, at least in part, to contact with substances found in the surrounding tissue fluids or cellular action.
  • bioabsorbable it is meant that the polymeric formulation is broken down and absorbed within the body of a mammal, for example, by a cell or tissue, “biocompatible” means that the polymeric formulation does not cause substantial tissue irritation or necrosis.
  • compositions as described herein can be administered together combined in a single dosage form or they can be administered separately, simultaneously or sequentially, each in its dosage form but as part of the same therapeutic treatment program or regimen. Separate administration of each compound, at different times and by different routes, will sometimes be recommended.
  • the dosage forms disclosed herein can be prepared by conventional methods known to a person ordinary skilled in the art.
  • the dosage of the pharmaceutical composition of the present invention may be appropriately determined with reference to the dosages recommended for the respective active components and can be selected according to the recipient, the age and body weight, current clinical status, administration time, dosage form, method of administration, and combination of the active components, among other factors.
  • the pharmaceutical composition of the present invention can show a marked synergistic effect compared with administration of either active component alone.
  • the pharmaceutical composition of the present invention develops sufficient efficacy with reduced doses as compared with the administration of any one of the active components alone, the side effects of the respective components can be reduced.
  • Another embodiment of the invention relates to the use of any of the compounds of Formula I or Formula II with a fibrate in the preparation of a medicament for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases.
  • PPD10558 was given under fasted and fed conditions. Serial samples were collected after dosing for plasma levels of PPD10558 and its active metabolite, PPD11901 :
  • Stage 2 was a 3-period crossover design in which PPD10558 (80 mg) and gemfibrozil (600 mg) were administered alone and together once daily for 6 days. There was 7-day washout between periods. Serial samples were collected after dosing on Day 6 for plasma levels of PPDl 0558, PPDl 1901, and gemfibrozil. Noncompartmental pharmacokinetic (PK) parameters were estimated for all analytes. An analysis of variance was performed on AUC and Cmax to assess the effect of food and the DDI.
  • PK pharmacokinetic
  • AUC of PPD10558 increased by 68% and Cmax decreased by 20% under the fed condition as compared to the fasted condition.
  • AUC and Cmax decreased by 30% and 55%, respectively, under fed conditions compared to the fasted condition.
  • Concomitant dosing with gemfibrozil increased the AUC and Cmax of PPDl 0558 by approximately 55%.
  • AUC increased by approximately 17% while there was no change in Cmax in the presence of gemfibrozil. There was no impact on gemfibrozil PK observed when gemfibrozil was coadministered with PPD 10558.
  • This example demonstrates that food had an impact on PK of PPD10558 by increasing the extent and decreasing the rate of absorption.
  • the reduction in PPDl 1901 exposure may be due to increased bile flow in the presence of food and the possibility of inhibition in biotransformation from PPD10558 to PPDl 1901 by food ingredients.
  • Gemfibrozil (an inhibitor of OATPIB 1 ) increased PPD 10558 exposures, but had minimal impact on PPDl 1901.
  • OATPIBl organic anion transporting polypeptide 1B1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un produit ou un médicament combiné contenant au moins un dérivé de pyrrole substitué et un ou plusieurs agents dyslipidémiques. L'invention concerne également des compositions pharmaceutiques contenant au moins un dérivé de pyrrole substitué inédit et un ou plusieurs agents dyslipidémiques, ainsi qu'au moins un excipient pharmaceutiquement acceptable. L'invention concerne, en outre, des méthodes de traitement ou de prophylaxie des maladies cardiovasculaires, de la maladie d'Alzheimer, de l'obésité, du diabète ou des maladies inflammatoires, impliquant l'administration à un mammifère en ayant besoin de quantités thérapeutiquement efficaces d'au moins un dérivé de pyrrole substitué selon l'invention et d'un ou plusieurs agents dyslipidémiques.
PCT/US2011/038769 2010-06-01 2011-06-01 Polythérapies WO2011153247A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35037610P 2010-06-01 2010-06-01
US61/350,376 2010-06-01

Publications (1)

Publication Number Publication Date
WO2011153247A1 true WO2011153247A1 (fr) 2011-12-08

Family

ID=45067059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038769 WO2011153247A1 (fr) 2010-06-01 2011-06-01 Polythérapies

Country Status (1)

Country Link
WO (1) WO2011153247A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159666A3 (fr) * 2015-03-31 2017-01-26 대원제약주식회사 Forme cristalline et procédé de préparation de celui-ci
CN106389438A (zh) * 2016-11-30 2017-02-15 郑州仁宏医药科技有限公司 益多酯在制备抗炎药物中的应用
WO2020082941A1 (fr) * 2018-10-24 2020-04-30 中国科学院昆明动物研究所 Utilisation du gemfibrosil et d'un dérivé de celui-ci pour le traitement et/ou la prévention d'une maladie neurodégénérative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination
US20080262074A1 (en) * 2004-05-24 2008-10-23 Pfizer, Inc. Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
US20080262074A1 (en) * 2004-05-24 2008-10-23 Pfizer, Inc. Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURDOCH ET AL.: "Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.", AMERICAN HEART JOURNAL, vol. 138, 1999, pages 151 - 155 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159666A3 (fr) * 2015-03-31 2017-01-26 대원제약주식회사 Forme cristalline et procédé de préparation de celui-ci
CN107438595A (zh) * 2015-03-31 2017-12-05 大元制药株式会社 晶型及其制备方法
CN107438595B (zh) * 2015-03-31 2021-05-18 大元制药株式会社 晶型及其制备方法
CN106389438A (zh) * 2016-11-30 2017-02-15 郑州仁宏医药科技有限公司 益多酯在制备抗炎药物中的应用
WO2020082941A1 (fr) * 2018-10-24 2020-04-30 中国科学院昆明动物研究所 Utilisation du gemfibrosil et d'un dérivé de celui-ci pour le traitement et/ou la prévention d'une maladie neurodégénérative

Similar Documents

Publication Publication Date Title
CN101711106B (zh) 取代的酰胺类的药物应用
CN101652359A (zh) 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类
SK287988B6 (sk) Composition, oral dosage form and use thereof
JP5490409B2 (ja) スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
JP2005533810A (ja) 新規な抗コレステロール組成物及びその使用方法
TWI407955B (zh) 高脂血症之預防及／或治療劑
RU2765218C2 (ru) Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
KR19990067698A (ko) 세로토닌 재흡수 억제제의 위장 효과를 극복하기 위한 5ht4수용체 길항제의 용도
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
EA021461B1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
WO2011153247A1 (fr) Polythérapies
CN101351209A (zh) 取代的酰胺的药学应用
CA2850100A1 (fr) Inhibiteurs de monoacylglycerol lipase pour le traitement de maladies metaboliques et de troubles apparentes
MXPA04004572A (es) Metodo para el tratamiento de enfermedades autoinmunes.
KR20060118557A (ko) 의약 조성물 및 조합물
JP6420923B1 (ja) 医薬
JP2021533190A (ja) ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法
US10456391B2 (en) Compositions and methods for treating cardiometabolic diseases and disorders
CA3206392A1 (fr) Combinaisons therapeutiques de rosuvastatine et de remetirom pour le traitement de troubles hepatiques ou de troubles lipidiques
US20210186950A1 (en) Combinations comprising tropifexor and cenicriviroc
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
WO2005102332A1 (fr) Agent thérapeutique pour l'arthrite déformante
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬
JPH10182596A (ja) 脂質代謝改善剤
KR20070102953A (ko) 고지혈증의 예방 및/또는 치료를 위한 의약

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11790340

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11790340

Country of ref document: EP

Kind code of ref document: A1